1. US Department of Health and Human Services: National Survey on Drug Use and Health Report: alcohol dependence or abuse: 2002, 2003, and 2004. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006:16, 1–4.
2. Harwood HJ. US Department of Health and Human Services: updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods and data. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2000, pp 1–17.
3. Jung YC, Namkoong K. Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention. Yonsei Med J 2006;47:167–178.
4. Kranzler HR. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000;35:537–547.
5. The National Center on Addiction and Substance Abuse: missed opportunity: national survey of primary care physicians and patients on substance abuse. New York, NY: The National Center on Addiction and Substance Abuse at Columbia University; 2000. pp i–v.
6. Wyatt SA, Vilensky W, Manlandro JJ, et al. Medical education in substance abuse: from student to practicing osteopathic physician. J Am Osteopath Assoc 2005;105:S18–S25.
7. Giannetti VJ, Sieppert JD, Holosko MJ. Attitudes and knowledge concerning alcohol abuse: curriculum implications. J Health Soc Policy 2002;15:45–58.
8. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol 2003;54:25–53.
9. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci 2002;22:3332–3337.
10. Dick DM, Bierut LJ. The genetics of alcohol dependence. Curr Psychiatry Rep 2006;8:151–157.
11. Brodie MS, Shefner SA, Dunwiddie TV. Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area in vitro. Brain Res 1990;508:65–69.
12. Yim HJ, Gonzales RA. Ethanol-induced increases in dopamine extracellular concentration in rat nucleus accumbens are accounted for by increased release and not uptake inhibition. Alcohol 2000;22:107–115.
13. Risinger FO, Freeman PA, Rubinstein M, et al. Lack of operant ethanol self-administration in dopamine D2 receptor knockout mice. Psychopharmacology (Berl) 2000;152:343–350.
14. Cunningham CL, Howard MA, Gill SJ, et al. Ethanol-conditioned place preference is reduced in dopamine D2 receptor-deficient mice. Pharmacol Biochem Behav 2000;67:693–699.
15. El-Ghundi M, George SR, Drago J, et al. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol 1998;353:149–158.
16. Jamensky NT, Gianoulakis C. Content of dynorphins and κ-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol Clin Exp Res 1997;21:1455–1464.
17. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res 1993;621:137–140.
18. Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617–1625.
19. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876–880.
20. Grobin AC, Matthews DB, Devaud LL, et al. The role of GABAA receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 1998;139:2–19.
21. Gorski TT. The Gorski-CENAPS model: an overview: science based approach. Independence, MO: Herald House Independence Press; 1997, pp 1–58.
22. Dawson DA, Grant BF, Stinson FS, et al. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 2005;100:281–292.
23. Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006;101:212–222.
24. Miller WR, Harris RJ. A simple scale of Gorski’s warning signs for relapse. J Stud Alcohol 2000;61:759–765.
25. Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal μ-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 2005;62:57–64.
26. Heinz A, Siessmeier T, Wrase J, et al. Correlation between dopamine D2 receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry 2004;161:1783–1789.
27. Volkow ND, Wang GJ, Fowler JS, et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996;20:1594–1598.
28. Heinz A, Siessmeier T, Wrase J, et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 2005;162:1515–1520.
29. Braus DF, Wrase J, Grüsser S, et al. Alcohol-associated stimuli activate the ventral striatum in abstinent alcoholics. J Neural Transm 2001;108:887–894.
30. Tiffany ST. Cognitive concepts of craving. Alcohol Res Health 1999;23:215–224.
31. George MS, Anton RF, Bloomer C, et al. Activation of prefrontal cortex and anterior thalamus in alcoholic subjects on exposure to alcohol-specific cues. Arch Gen Psychiatry 2001;58:345–352.
32. Myrick H, Anton RF, Li X, et al. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology 2004;29:393–402.
33. US Department of Health and Human Services: helping patients who drink too much: a clinician’s guide. Rockville, MD: National Institute on Drug Abuse and Alcoholism; 2005, pp 1–31.
34. Rosenthal RN. Intramuscular naltrexone: targeting adherence in alcohol dependency treatment. Curr Psychiatry 2006;5:106–111.
35. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006;40:383–393.
36. Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72:1775–1780.
37. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA 1986;256:1449–1455.
38. Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. JAMA 2006;295:2003–2017.
39. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J Psychiatry Neurosci 2001;26:304–318.